Table 2.
Randomized trials including SRT treatment in OMD.
| Type of Cancer | Targetable Mutations | Maximum No. of Lesions |
Arms | No. of Patients |
mPFS (Months) | p | mOS (Months) | p |
|---|---|---|---|---|---|---|---|---|
| NSCLC | Not permitted | 6 | SRT + CT | 14 | 9.7 | NR | ||
| CT | 15 | 3.5 | 0.01 | 17.0 | NR | |||
| CRC | Permitted | 10 liver met | RFA + resection + CT | 51 | 16.8 | 45.6 | ||
| CT | 57 | 9.9 | 0.005 | 40.5 | 0.01 | |||
| NSCLC | Permitted | 3 | SRT or surgery | 25 | 14.2 | 41.2 | ||
| Observation or CT | 24 | 4.4 | 0.022 | 17.0 | 0.034 | |||
| Breast, CRC, NSCLC, prostate, others | Permitted | 5 | SRT + SC | 66 | 12.9 | 41.0 | ||
| SC | 33 | 6.0 | 0.0012 | 28.0 | 0.09 | |||
| NSCLC | Only EGFR-mutated cancers | 5 | SRT + TKI | 68 | 20.2 | 25.5 | ||
| TKI | 65 | 12.5 | <0.001 | 17.4 | <0.001 |
CRC: colorectal cancer; CT: chemotherapy; met: metastases; mOS: median overall survival; mPFS: median progression-free survival; NSCLC: non-small cell lung cancer; RFA: radio-frequency ablation; SC: Standard of Care; SRT: stereotactic radiotherapy; TKI: tyrosine kinase inhibitor.